Ali Nagy Shelbaya

Ali Nagy Shelbaya

Auto-generated profile, based on publicly available information

Ali Nagy Shelbaya

Faculty of Medicine, New Mansoura University, New Mansoura, Egypt

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2026 in ASIDE Internal Medicine
Verified
Journal Article
Open access
PDF file
OAOmar Khaled Abdelsalam
Omar Khaled Abdelsalam
MAMousa Almasalma
Mousa Almasalma
ASAli Nagy Shelbaya
Ali Nagy Shelbaya
AAAhmed Raja Albishti
Ahmed Raja Albishti
MKMohamed H. Khalil
Mohamed H. Khalil
AAAsmaa Zakria Alnajjar
Asmaa Zakria Alnajjar
Background: Multiple sclerosis (MS) is an immune-mediated disorder characterized by demyelination within the central nervous system, resulting in fatigue, pain, cognitive dysfunction, and motor impairment. Remotely supervised transcranial direct current stimulation (RS‑tDCS) is a noninvasive, low-cost, home-based intervention that modulates neuronal excitability and enhances neural network function, potentially benefiting individuals with MS. This meta-analysis aimed to evaluate the efficacy of RS‑tDCS in MS. Methods: A systematic search was conducted in PubMed, Web of Science, Scopus, and the Cochrane Library for randomized controlled trials (RCTs) evaluating RS‑tDCS in MS. The primary outcome was information‑processing speed. Statistical analyses were performed using R software (version 4.5.0) and a random‑effects model to calculate pooled standardized mean differences (SMDs) and mean differences (MDs) with 95% confidence intervals (CIs). Risk of bias was assessed using the Cochrane ROB‑2 tool. Results: Five RCTs, most featuring co-interventions alongside RS-tDCS in both study arms and one specifically targeting MS patients with cannabis use disorder, including 291 participants, were analyzed. Active RS‑tDCS did not significantly improve information‑processing speed (SMD = 0.20; 95% CI: –0.06 to 0.45; P = 0.13, n studies: 4). No significant effects were observed for secondary outcomes. Conclusion: Evidence from five heterogeneous RCTs, predominantly featuring co-interventions, shows no clear benefit of RS-tDCS for MS cognitive or functional outcomes (very low to low certainty). This highlights substantial uncertainty; larger standalone trials are required.

31 October 2026 in Epilepsy Research
Verified
Journal Article
Closed access
ASAli Nagy Shelbaya
Ali Nagy Shelbaya
MAMohammed Ali
Mohammed Ali
DEDina Elsayed
Dina Elsayed
HAHala AbouShawareb
Hala AbouShawareb
AMAlaa Mohamed
Alaa Mohamed
MMMostafa Meshref
Mostafa Meshref